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Objectives: Safe and effective device closure of ventricular septal defects remains
a challenge. We have developed a transcardiac approach to close ventricular septal
defects using a patch delivery and fixation system that can be secured under real-
time three-dimensional echocardiographic guidance.
Methods: In Yorkshire pigs (n5 8) a coring device was introduced into the left ven-
tricle through a purse-string suture placed on the left ventricular apex, and a muscular
ventricular septal defect was created. The patch deployment device containing a 20-
mm polyester patch was advanced toward the ventricular septal defect through
another purse-string suture on the left ventricular apex, and the patch was deployed
under real-time three-dimensional echocardiographic guidance. The anchor delivery
device was then introduced into the left ventricle through the first purse-string suture.
Nitinol anchors to attach the patch around the ventricular septal defect were deployed
under real-time three-dimensional echocardiographic guidance. After patch attach-
ment, residual shunts were sought by means of two-dimensional and three-dimen-
sional color Doppler echocardiography. The heart was then excised, and the
septum with the patch was inspected.
Results:A ventricular septal defect was created in the midventricular (n5 4), anterior
(n 5 2), and apical (n 5 2) septum. The mean size was 9.8 mm (8.2–12.0 mm), as
determined by means of two-dimensional color Doppler scanning. The ventricular
septal defects were completely closed in 7 animals. In one a 2.4-mm residual shunt
was identified. No anatomic structures were compromised.
Conclusions: Beating-heart perventricular muscular ventricular septal defect closure
without cardiopulmonary bypass can be successfully achieved by using a catheter-
based patch delivery and fixation system under real-time three-dimensional echocar-
diographic guidance. This approach might be a better alternative to cardiac surgery or
transcatheter device closure.
A
lthough pediatric cardiopulmonary bypass and cardiac repair of intracardiac
defects have matured over the last decades, becoming relatively safe, they
remain invasive procedures associated with the potential, albeit rare, for
neurologic complications among other complications.1 At the same time, there is
an increasing amount of basic, translational, and clinical research currently being con-
ducted in the area of beating-heart repairs, including transapical aortic valve and per-
ventricular pulmonary valve implantation,2-4 transcardiac ventricular septal defect
(VSD) closure,5,6 and mitral valvuloplasty and atrial septal defect (ASD) closure.7-9
A key component enabling such procedures is the advance in imaging technology,
which allows real-time visualization of heart structures and instruments while the
heart is beating. Three-dimensional ultrasonographic (3DUS) imaging has made
significant progress in the past few years, with improvements in spatial and temporal
Video clip is available online.
From the Departments of Cardiac Surgery
and Anesthesia,a Children’s Hospital Bos-
ton, Harvard Medical School, Boston,
Mass; the Department of Pediatric Cardio-
logy,b Kardiozentrum, La Paz, Bolivia; the
Department of Pediatric Cardiothoracic
Surgery,c Columbus Children’s Hospital,
Columbus, Ohio; the Department of Pediat-
ric Cardiology,d Grosshadern University
Hospital, University of Munich, Munich,
Germany; and the Ultrasound Division,e
Philips Medical Systems, Andover, Mass.
Supported in part by National Institute of
Health grants no. HL-073647 and HL-
71128 (PJdN).
Ivan Salgo is employed by Philips Health-
care.
Address for reprints: Emile A. Bacha, MD,
Department of Cardiac Surgery, Children’s
Hospital Boston, Harvard Medical School,
300 Longwood Avenue, Boston, MA
02115 (E-mail: emile.bacha@cardio.
chboston.org).
J Thorac Cardiovasc Surg 2008;135:603-9
0022-5223/$34.00
Copyright  2008 by The American Asso-
ciation for Thoracic Surgery
doi:10.1016/j.jtcvs.2007.09.045The Journal of Thoracic and Cardiovascular Surgery c Volume 135, Number 3 603
Evolving Technology Vasilyev et al
ETAbbreviations and Acronyms
ASD 5 atrial septal defect
LV 5 left ventricle
RT3DE 5 real-time three-dimensional echocardiography
3D 5 three-dimensional
3DUS 5 three-dimensional ultrasonography
VSD 5 ventricular septal defect
resolution. The ease of data acquisition, real-time three-di-
mensional (3D) volume rendering, the ability to focus on a
specific anatomic structure, and a variety of additional quan-
tification tools have enabled virtually routine application of
3DUS in cardiology practice.10,11 Real-time 3D echocardiog-
raphy (RT3DE) is an ideal imaging modality for septal defect
closure because it provides precise anatomic images of com-
plex anatomic structures, such as the atrial or ventricular sep-
tum and margins of septal defects. Obstacles to application of
3DUS, such as acoustic interference from metallic instru-
ments caused by shadowing and side-lobe artifacts in the field
of view, can be minimized with instrument modifications,
such as the application of surface coating and by varying
the angle of instrument navigation with respect to the ultraso-
nographic probe.12 The high frame rates currently achieved
with RT3DE obviate the need for electrocardiographic or re-
spiratory gating for image acquisition. We have recently
demonstrated that epicardial RT3DE provides adequate ana-
tomic detail for surgical task performance in an in vitro
model7 and in vivo model of beating-heart patch ASD
closure.8,9
The aim of the present animal study was to investigate the
feasibility and efficacy of beating-heart transcardiac closure
of a muscular VSD by using our patch delivery and minian-
chor deployment system under RT3DE guidance.
Materials and Methods
The experimental protocol was approved by the Children’s Hospital
Boston Institutional Animal Care and Use Committee. All animals
received humane care in accordance with the 1996 ‘‘Guide for the
care and use of laboratory animals’’ recommended by the US
National Institutes of Health.
Yorkshire pigs (70–80 kg, n5 8) were anesthetized by means of
intramuscular injection of tiletamine/zolazepam (7 mg/kg) and xyla-
zine (4 mg/kg). The animals were intubated with a cuffed endotra-
cheal tube and ventilated with a pressure-control ventilator
(Healthdyne 105; Healthdyne Technologies, Marietta, Ga); anesthe-
sia wasmaintained with 1% to 2% isoflurane. The electrocardiogram
and arterial blood pressure were continuouslymonitored. A left ante-
rolateral thoracotomy in the fourth intercostal space was performed,
and stay sutureswere placed on the pericardium to optimize access to
the left ventricle (LV) free wall and the apex. RT3DEwas performed
by using the X4 matrix probe on a SONOS 7500 system (Philips
Medical Systems, Andover, Mass). The ultrasonographic probe
was inserted into a sleeve (CIVCO Medical Instruments, Kalona,604 The Journal of Thoracic and Cardiovascular Surgery c MaIowa) filled out with an ultrasound gel (Parker Laboratories, Inc,
Fairfield, NJ) providing approximately 2 cm of standoff. The outer
surface of the sleeve was lubricated with 0.9% sodium chloride solu-
tion and applied to the surface of the LV. After intravenous heparin
administration (100 U/kg), a VSD was created solely under RT3DE
guidance. Through a 3-0 polypropylene felt pledget–reinforced
purse-string suture placed on the apical portion of the left ventricular
free wall, an original 10-mm coring device was introduced into the
LVand advanced through the ventricular septum.This created amus-
cular VSD, which was confirmed bymeans of two-dimensional (2D)
and 3D color Doppler echocardiography.
The VSD was then closed with a polyester patch by using our
previously described patch delivery and fixation system, as
Figure 1. Patch deployment device: front view (A), rear view (B),
and minianchors (C). Polyester patch material is attached to the
nitinol frame by using a 0.1-mm release nitinol wire (red arrows).
During deployment, the arms of the anchor (a) penetrate the patch
and attach it to the septal tissue, while the loop (l) stays on the
front side of the patch.rch 2008
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eter-based patch delivery device and the patch fixation device. The
patch delivery device consists of a self-expanding nitinol frame and
a grip. A polyester patch is appropriately trimmed and then attached
to the frame with a 0.1-mm nitinol release wire (Figure 1, A and B).
The device is delivered through a 9F sheath, and the frame with the
patch is deployed through the end of the sheath and allowed to ex-
pand. The polyester patch is attached to the septum by using nitinol
minianchors (Figure 1, C) deployed with a pistol-type anchor deliv-
ery device.
The patch deployment devicewas introduced through a second 3-
0 polypropylene purse-string suture in the LV and advanced toward
the VSD under RT3DE guidance, staying parallel to the ventricular
septum and away from the papillary muscles and the mitral valve
chordae and leaflets. Once the frame with the patch was deployed
and placed over the VSD, the fixation device was introduced into
the LV and advanced toward the patch (Figure 2). The anchors
were deployed by using a fixation device, one by one around the cir-
cumference of the patch. This latter maneuver was also performed
under RT3DE guidance and in 2 steps. First, the arms of the anchor
were deployed, and successful penetration of both the patch material
and the septum was confirmed with tactile sensation and applying of
gentle traction force on the deployed anchor. Next, the anchor loop
was fully deployed, and the anchor was released from the fixation
device. After the patch was fixed to the septum, the release wire
was removed, allowing separation of the patch from the frame, and
the frame was withdrawn into the sheath. This technique leaves
only the polyester patch and nitinol anchors inside the heart. After
Figure 2. Scheme of the procedure. Explanations are shown in the
text. LV, Left ventricle; RV, right ventricle; VSD, ventricular septal
defect.The Journal of ThoFigure 3. Color Doppler images of the created ventricular septal
defect. A, Two-dimensional color Doppler scanning. B, Three-
dimensional color Doppler scanning. The yellow arrow points to
the orifice of the ventricular septal defect on the left side of the
ventricular septum. C, The same three-dimensional color Doppler
image with suppression of the black-and-white image. Yellow
dashed lines demonstrate the ventricular septal defect tunnel
inside the ventricular septum. LV, Left ventricle; RV, right ventricle;
VSD, ventricular septal defect.racic and Cardiovascular Surgery c Volume 135, Number 3 605
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performed to look for any residual shunts. Finally, the animal was
sacrificed, the heart was excised, and the efficacy of closure and
patch fixation was determined by means of direct inspection.
Results
To safely perform the entire procedure solely under RT3DE
guidance, the optimal orientation of the epicardial ultrasono-
graphic probe and different insertion points for the devices
was determined in the first 2 animals. The transducer was
positioned at approximately 45 to the surface of the left ven-
tricular free wall, close to the atrioventricular groove, aiming
toward the apex. With this orientation, nearly the entire left
ventricular chamber was able to be visualized, and the
devices could be navigated from the insertion points toward
the ventricular septum under constant 3DUSmonitoring. The
devices were introduced coaxially into the LV from the apical
region. This orientation provided optimal ergonomics for
device manipulation, adequate visualization for safe device
navigation inside the LV, and minimized trauma of the left
ventricular wall, avoiding the coronary arteries (Figure 2).
VSD Creation
TheVSDswere created in themidventricular (n5 4), anterior
(n5 2), and apical (n5 2)muscular septum. Themean size of
the VSDwas 9.8mm (8.2–12.0mm), as determined bymeans
of 2D colorDoppler echocardiography (Figure 3,A). Success-
ful creation of the defects was also confirmed by means of 3D
color Doppler echocardiography (Figure 3,B andC). The size
of the patch used was 20 mm in all the cases.
VSD Closure
Representative sequential RT3DE images obtained during
VSD closure are shown in the right column of Figure 4; the
left column shows ex vivo demonstration of the procedure
for better comprehension. The VSDs were closed completely
in 7 animals, with no residual shunts detected by means of
Figure 4. Ventricular septal defect patch closure demonstration
ex vivo (left column) and sequence of the real-time three-dimen-
sional echocardiographic (RT3DE) images acquired during the
procedure (right column): view from the left ventricle. A and B,
The patch is delivered through an introducer sheath toward the
ventricular septal defect (yellow arrowhead). C and D, After the
frame expands (blue arrowheads) and the patch covers the ven-
tricular septal defect, it is attached to the ventricular septum by
the nitinol minianchors (blue dots). Note the segmented polymer
coating of the anchor-deployment device for optimizing the instru-
ment visualization under ultrasonographic guidance. E and F, All
the anchors are deployed, and the patch is completely attached
to the septum, closing the ventricular septal defect. G and H,
The release wire is removed, and the frame is withdrawn into
the introducer sheath. The patch (red arrowheads) is left attached
to septum. I and J, Final view: patch and anchors (blue dots).rch 2008
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10) anchors was used per case. In one animal a 2.4-mm
residual defect was identified around the edge of the patch.
That animal had the largest VSD (12 mm) of the series,
with the VSD having been created in the midventricular sep-
tum by means of repeated coring of the muscular tissue. As
a result, the tissue around the VSD was porous and friable,
and it was difficult to transfix the patch to the septum with
the anchors.
Direct inspection of the septum after excision of the heart
confirmed the intraoperative echocardiographic findings
(Figure 5, B and C). The anchors consistently penetrated
the patch material and the ventricular septal myocardium.
The VSDs were sealed completely in 7 cases. In one animal
residual communication of 2 mm was found. No other ana-
tomic structures in the LV and right ventricle were compro-
mised in any of the cases.
Discussion
The present study demonstrates that (1) muscular VSDs can
be successfully created in pigs by using a perventricular cor-
ing device and (2) muscular VSDs can be closed under
RT3DE guidance on the beating heart through a left perven-
tricular approach by using a patch anchored to the left side of
the septum (see Video 1).
Closure of an isolated VSD is one of the oldest cardiac pro-
cedures, beginningwith the first successful closure in 1955 by
C. Walton Lillehei.13 The procedure currently enjoys a low
complication and mortality rate, with surgical repair remain-
ing the mainstay of therapy. Percutaneous device closure
techniques have recently emerged and have had mixed suc-
cess.14 Although device closure has been successfully applied
in cases of multiple muscular VSDs or midmuscular isolated
VSDs, for example, it has thus far not proved to be superior to
cardiac surgery when it comes to complete closure of the de-
fects. FormembranousVSDs, development of complete heart
block, sometimes occurring late after device implantation, has
been a source of concern.15 Furthermore, the presence of an
often bulky device in close proximity to the aortic valve and
left ventricular outflow tract has the potential for resulting
in other late complications. Furthermore, the chordae of the
subvalvar apparatus of the mitral and tricuspid valves and
the integrity of the aortic valve cusps are at risk during
repeated passages of wires and sheaths into the heart. The per-
ventricular techniques, developed clinically for muscular
Figure 5. A, Two-dimensional color Doppler image of the closed
ventricular septal defect. The patch (red arrowheads) completely
sealed the ventricular septal defect. B and C, Postmortem photo-
graphs: view from the right ventricle (B) and left ventricle (C).
The patch is properly fixed around the 10-mm ventricular septal
defect. No residual defect is present. LV, Left ventricle; RV, right
ventricle; VSD, ventricular septal defect.oracic and Cardiovascular Surgery c Volume 135, Number 3 607
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avoid some of these hazards, such as damage to the valves, be-
cause the VSD is approached directly at the ventricular level.
No valves are crossed, and the angle of approach is close to
90 to the plane of the septum, providing much more favor-
able conditions for crossing of the VSD and device deploy-
ment. However, perventricular device–based procedures
still had significant drawbacks in terms of device bulkiness
(eg, expansion in a hypertrophied right ventricular apex) or re-
sidual VSD from undersizing or malpositioning of the device.
Devices themselves, as demonstrated from recent reports,16
can erode through cardiac structures, such as the aortic root.
Endocarditis and thromboembolic episodes are other feared
complications.17
The present procedure circumvents many of these compli-
cations. There is no need to first cross the VSD with a guide-
wire, one of the major initial difficulties in any device-based
VSD closure. The catheter-mounted patch delivery device
allows for a left-sided approach and is easily positioned
and deployed over the VSD by using RT3DE. Because the
patch is anchored on the left side of the septum, it is subjected
to 4- to 5-fold higher pressure in systole, compressing it
against the septal tissue, likely rendering small residual
VSDs inconsequential in the long term. Unlike with open sur-
gical repairs, in which sutures have to be closely aligned to
prevent residual VSDs, anchors have to secure the patch in
place but do not have to be very closely spaced. In our studies
the anchors were secure and completely penetrated the mus-
cular septal tissue. By virtue of its ventricular approach, this
procedure retains the advantages of (right-sided) perventric-
ular VSD closure, avoiding the crossing of valves. In addi-
tion, as opposed to the tricuspid valve, which has many
septal attachments, there are no mitral valve papillary mus-
cles based on the ventricular septum. This therefore provides
more favorable conditions to operate in the beating-heart
RT3DE-guided environment because there is no nearby sub-
valvular apparatus.
Compared with our previous experience of RT3DE-
guided ASD patch closure,9 we encountered few important
technical differences between these 2 procedures. High ve-
locity and contractile force of the ventricular septum, unlike
atrial septal motion, makes free-hand deployment of the first
anchors crucial, which in inexperienced hands can lead to
torn myocardium and dislodged anchors. To address the
problems with collision with the rapidly moving septum
and to simplify anchor fixation to a moving target, we are de-
veloping a motion-compensation tool that tracks the motion
of the septum in real time and might provide an easier method
of patch fixation.18 Initial visualization and, more impor-
tantly, tracking of the muscular VSD with 3DUS imaging
throughout the procedure is challenging. To address this
problem, our group has developed an image-processing algo-
rithm for block flowASD detection and tracking.19 This tech-
nique has to be further optimized for real-time VSD tracking608 The Journal of Thoracic and Cardiovascular Surgery c Main a cluttered operative field in the left ventricular cavity. Fi-
nally, because there are no naturally occurring large-animal
models of muscular VSDs, we developed this model using
an original coring device to create the defects. The muscular
VSDs were easily created by using the same entry point as
was later used for the anchoring device. A final potential dis-
advantage is the possibility of pseudoaneurysm formation at
the left ventricular free wall puncture site.
In summary, this study demonstrates that muscular VSDs
can be successfully created and closed using our patch deliv-
ery device under RT3DE guidance on the beating heart in
a large animal. In future work, we aim to test a similar tech-
nique for membranous VSD closure using Yucatan pigs.6
We thank Mr Randal S. McKenzie for the illustrations.
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